Oncology, haematology, acute medical, emergency and community-based teams who support, treat or come into contact with patients who are receiving a course of chemotherapy as a treatment for their cancer.
To examine the NICE guideline recommendations for the prevention, identification and management of neutropenic sepsis in patients having cancer treatment and to apply the knowledge you’ve gained to practice. This e-learning tool will take you about an hour to complete.
NICE clinical guideline 151 Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients was published in September 2012. Neutropenic sepsis is a potentially fatal complication following anticancer treatments (particularly chemotherapy). This guideline aims to improve outcomes by providing evidence-based recommendations on the prevention, identification and management of this life-threatening complication.
This e-learning tool has a number of learning activities to help you implement the guidelines and improve patient outcomes by focusing on the five key priorities for implementation. It is divided into four main sections: background, supporting patients – acting fast, first hour and ongoing management.
On completion of this tool you should be able to:
- recognise the signs and symptoms of neutropenic sepsis
- advise patients of the risk factors for neutropenic sepsis and how they can access support and advice
- identify the criteria for referral of patients with suspected neutropenic sepsis
- describe the policies and assessment tools that are available to support the identification and management of neutropenic sepsis
- assess patients to identify the appropriate treatment decisions for the ongoing management of neutropenic sepsis
- compare your current practice against the guideline and apply the key recommendations that are appropriate to your role
- produce an action plan to address any barriers or areas for development.